How is SpotitEarly’s mission leading the global fight against cancer?

Imagine a world where early detection is the norm, transforming the fight against cancer

At SpotitEarly, we are turning this idea into reality by pioneering a new era of cancer screening. Our aim is clear: to save lives by developing a non-invasive test for multiple types of cancer, combining the remarkable scent detection abilities of dogs with cutting-edge AI. Through this groundbreaking combination, we can make early disease detection accurate, affordable and accessible.

The current lack of innovative screening solutions means that, for example, cancer is still among the leading causes of death globally. One of the key reasons for this is the low percentage of cases identified early. In England, for example, research from 2021 found that only 54.4% of new cancer diagnoses were made early (at stage 1 or 2), and that’s the highest % ever recorded.

“We think early cancer detection is one of humanity’s largest and most complicated challenges,” says Roi Ophir, Chairman and Co-founder of SpotitEarly. “That’s why we’re focused on it as our mission for the coming years.” As Dr. Shlomi Madar, SpotitEarly’s CEO puts it: “SpotitEarly is revolutionizing early cancer screening.”

Why early detection matters

Most importantly, when cancer is diagnosed at an early stage, patient survival rates are significantly higher — up to 89% compared to just 21% for late-stage diagnoses. However, early detection not only saves lives but also reduces the financial burden on patients and healthcare systems. Treating cancer in its advanced stages often costs twice as much as treating it before it spreads.

In a recent peer-reviewed, published research paper, SpotitEarly was able to detect cancer in breath samples with over 90% accuracy across multiple cancer types. This will help us to create a more sustainable, effective approach to cancer care. Our innovative Breath Test also directly addresses the limitations of current cancer screening tests, which are often invasive, costly and prone to false positives.

Our technology: Where nature meets AI

At the heart of SpotitEarly’s solution is a unique integration of two extraordinary capabilities: the unparalleled scent detection of our canine partners and the analytical power of AI.

• After training, our dogs can identify specific volatile organic compounds (VOCs) associated with cancer in breath samples. Their extraordinary accuracy in detecting early-stage cancers has been validated through numerous rigorous clinical trials. Roi Ophir explains: “When I saw dogs’ potential for detecting medical conditions like cancer, I was amazed and knew we had to build something meaningful around it.”
• Complementing the dogs’ natural abilities, LUCID, our proprietary AI system and laboratory platform, cross-validates results, reviewing data in real-time to enhance reliability and assign confidence scores. “LUCID isn’t just about analyzing breath samples,” says Dr. Tal Shaharabany, SpotitEarly’s AI Lead. “It’s about refining insights, monitoring canine responses and continuously improving through deep learning.”

This combination enables SpotitEarly to transform simple, non-invasive breath samples into highly accurate diagnostic results, updating the way we approach early cancer detection. By seamlessly integrating advanced technology with user-friendly processes, SpotitEarly makes early screening more accessible, less intimidating, and more effective for patients and healthcare providers alike.

Detecting multiple cancer types

“The future of diagnostics lies in the ability to detect multiple types of cancers in one test. This will also help people to better adhere to their screening guidelines ” says Udi Bobrovsky, SpotitEarly’s COO and Co-founder.

Our approach represents a paradigm shift in cancer care. We’re able to check for multiple cancer types in a single screening test – expanding the number of cancers that are identifiable and moving diagnostics beyond single-cancer tests. By detecting cancer before symptoms arise, the company also has the potential to improve treatment outcomes dramatically while reducing overall healthcare costs.

Driving change through proactive care

SpotitEarly is committed to making this the global standard. We envision a future where regular screening becomes as routine as an annual physical exam. This can also help address disparities in cancer screening, ensuring equitable access to life-saving diagnostic insight.

Through our innovative technology and unwavering commitment to our mission, we are working to reduce the global cancer burden and transform healthcare for the better.

As Roi Ophir reflects, “The need for non-invasive and pre-emptive solutions has never been greater. As healthcare becomes more expensive and less accessible, at-home tests and predictive medicine are key to bridging the gap.”

By focusing on breath-based screening, SpotitEarly is also perfectly aligned with major trends in healthcare innovation. “We’re sitting at the intersection of AI, big data, and non-invasive testing,” Ophir continues. “This is where the future of health tech is headed and we’re ahead of the curve.”

The future is within reach

At SpotitEarly, our ambition is bold but achievable: to be the world’s most accurate and affordable early cancer detection solution promoting proactive care globally and saving peoples’ lives.

With the combined power of canine olfaction, advanced AI and an exceptional team, SpotitEarly is not just imagining this future – we are already building it. Together, we’re shifting the focus to early detection, saving lives and reshaping the narrative around cancer care.

Join us in making this vision a reality. One breath, one test, one life at a time.